Results 1 to 10 of about 55,739 (140)

Sorafenib and Sunitinib [PDF]

Oncologist, 2009
Learning Objectives After completing this course, the reader will be able to: Enumerate the clinical indications for sorafenib and sunitinib therapy.Describe the mechanism of action and the pharmacokinetics of sorafenib and sunitinib.Analyze the toxicity profile and appraise the therapeutic effects associated with sorafenib and sunitinib.
Aerang Kim, Frank Balis, Brigitte Widemann   +2 more
exaly   +3 more sources

Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance

Cells, 2022
Sorafenib is a small molecule that blocks tumor proliferation by targeting the activity of multi-kinases for the treatment of advanced hepatocellular carcinoma (HCC). Increasing sorafenib resistance following long-term treatment is frequently encountered.
Yung-Sheng Chang, Chien-Wei Su, San-Chi Chen, Yen-Ying Chen, Yuh-Jin Liang, Jaw-Ching Wu   +5 more
doaj   +1 more source

Sorafenib as an Inhibitor of RUVBL2 [PDF]

Biomolecules, 2020
RUVBL1 and RUVBL2 are highly conserved ATPases that belong to the AAA+ (ATPases Associated with various cellular Activities) superfamily and are involved in various complexes and cellular processes, several of which are closely linked to oncogenesis.
Nardin Nano, Francisca Ugwu, Thiago V. Seraphim, Tangzhi Li, Gina Azer, Methvin Isaac, Michael Prakesch, Leandro R. S. Barbosa, Carlos H. I. Ramos, Alessandro Datti, Walid A. Houry   +10 more
openaire   +5 more sources

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib

Pharmaceutics, 2020
Prior studies have demonstrated an organic anion transporter 6 (OAT6)-mediated accumulation of sorafenib in keratinocytes. The OAT6 inhibitor probenecid decreases sorafenib uptake in skin and might, therefore, decrease sorafenib-induced cutaneous adverse
Koen G. A. M. Hussaarts, Leni van Doorn, Karel Eechoute, Jeffrey Damman, Qiang Fu, Nadia van Doorn, Eric D. Eisenmann, Alice A. Gibson, Esther Oomen-de Hoop, Peter de Bruijn, Sharyn D. Baker, Stijn L. W. Koolen, Teun van Gelder, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen, Alex Sparreboom, Sander Bins   +16 more
doaj   +1 more source

Anterior gradient 2 induces resistance to sorafenib via endoplasmic reticulum stress regulation in hepatocellular carcinoma

Cancer Cell International, 2023
Background Hepatocellular carcinoma (HCC) accounts for almost 80% of all liver cancer cases and is the sixth most common cancer and the second most common cause of cancer-related death worldwide.
Hung-Wen Tsai, Yi-Li Chen, Chun-I Wang, Ching‑Chuan Hsieh, Yang-Hsiang Lin, Pei-Ming Chu, Yuh-Harn Wu, Yi-Ching Huang, Cheng-Yi Chen   +8 more
doaj   +1 more source

Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research, 2022
Background Macropinocytosis, an important nutrient-scavenging pathway in certain cancer cells, allows cells to compensate for intracellular amino acid deficiency under nutrient-poor conditions.
Jun-Kyu Byun, Seunghyeong Lee, Gil Won Kang, Yu Rim Lee, Soo Young Park, Im-Sook Song, Jae Won Yun, Jaebon Lee, Yeon-Kyung Choi, Keun-Gyu Park   +9 more
doaj   +1 more source

Artesunate Regulates Neurite Outgrowth Inhibitor Protein B Receptor to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells

Frontiers in Pharmacology, 2021
The multireceptor tyrosine kinase inhibitor sorafenib is a Food and Drug Administration-approved first-line drug for the treatment of advanced liver cancer that can reportedly extend overall survival in patients with advanced hepatocellular carcinoma ...
Wubin He, Xiaoxu Huang, Bradford K. Berges, Yue Wang, Ni An, Rongjian Su, Yanyan Lu   +6 more
doaj   +1 more source

Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research, 2022
Background Hepatocellular carcinoma (HCC) is one of the most malignant tumors and the fourth leading cause of cancer-related death worldwide. Sorafenib is currently acknowledged as a standard therapy for advanced HCC.
Danyang Li, Yingcheng Yao, Yuhan Rao, Xinyu Huang, Li Wei, Zhimei You, Guo Zheng, Xiaoli Hou, Yu Su, Zac Varghese, John F. Moorhead, Yaxi Chen, Xiong Z. Ruan   +12 more
doaj   +1 more source

Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines. [PDF]

PLoS ONE, 2017
BACKGROUND:Despite recent advances in treatment strategies, it is still difficult to cure patients with hepatocellular carcinoma (HCC). Sorafenib is the only approved multiple kinase inhibitor for systemic chemotherapy in patients with advanced HCC.
Yuki Haga, Tatsuo Kanda, Masato Nakamura, Shingo Nakamoto, Reina Sasaki, Koji Takahashi, Shuang Wu, Osamu Yokosuka   +7 more
doaj   +1 more source

Efficacy of radiofrequency ablation following transarterial chemoembolisation combined with sorafenib for intermediate stage recurrent hepatocellular carcinoma: a retrospective, multicentre, cohort studyResearch in context

EClinicalMedicine, 2023
Summary: Background: The evidence of radiofrequency ablation (RFA) following transarterial chemoembolisation (TACE) combined with sorafenib for intermediate-stage recurrent hepatocellular carcinoma (RHCC) is limited.
Xiao-Hui Wang, Wen-Bin Duan, Wei Liang, Hui Li, Xiao-Yan Xie, Shao-Qiang Li, Min-Shan Chen, Ping Liang, Xian-Hai Mao, Qun-Fang Zhou   +9 more
doaj   +1 more source